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Abstract
Background: Lymphedema is a disease of the skin and subcutaneous tissue resulting from a disturbance in
lymph flow. Anyone can be affected, and causes include cancer therapy when lymph nodes are removed or
irradiated, the parasitic disease lymphatic filariasis, and damage caused by exposure to irritant soils known as
podoconiosis. Manifest lymphedema is progressive and a major contributor to disability, stigma, and social
isolation for affected people. Although the pathogenesis of connective tissue changes in lymphedema will
follow a similar course regardless of the disease of causation, several systems are used to stage progression.
Disparity in these staging systems leads to inconsistency in reporting of the severity of lymphedema and
prevents meta-analysis of research results. In the global health environment, integrated morbidity management
for chronic illness is essential to meet the needs of affected people and to be sustainable for health care systems.
Clinical descriptors for staging criteria within each system may assist clinicians in assessment and provide a
format for consistency in reporting by lymphedema researchers.
Methods and Results: Lymphedema staging systems used in oncology, filariasis, and podoconiosis settings
were reviewed and the assessment techniques, diagnostic procedures, and clinical observations used by each
system are described. The most commonly used staging systems are compared to identify similarities, and a
matrix approach to lymphedema staging is proposed.
Conclusion: A universal staging system would contribute to more consistent reporting of research on and
clinical management of lymphedema arising from multiple causes.
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Introduction
Lymphedema is a leading cause of disability worldwide,yet it remains underdiagnosed, under-researched, and
underfunded in most health systems.1–5 It is a connective
tissue disease that occurs in the subcutaneous tissues when
normal lymphatic clearance is disturbed.6 The etiology of
lymphedema can be wide ranging, and pathogenesis of the
resulting connective tissue disease may also vary.7–10 Despite
these variations, when lymph flow is impeded for any reason,
an accumulation of protein-rich fluid in the loose connective
tissue follows. This excess fluid is eventually replaced by
fibrotic induration and fat deposition. Regardless of the
cause, long-term reduction in lymphatic activity will always
lead to chronic inflammation, skin pathologies, and an in-
creased risk of bacterial and fungal infections.11,12 Untreated
lymphedema is progressive and beyond the earliest stages
management becomes increasingly difficult and resource
intensive.4,13
Lymphedema can affect anyone. Male, female, young or
old, rich or poor, in every country there will be people living
with, or at risk of developing lymphedema. Global prevalence
estimates are as many as 250 million people worldwide.14 The
major single cause is lymphatic filariasis (LF), a parasitic dis-
ease affecting 17million people in developing tropical countries
where it is closely associated with poverty.15 At the other end of
the spectrum, breast-cancer-related lymphedema affects up to
40% of breast cancer survivors.16 which probably accounts for
less than 1 million people worldwide, mostly women in de-
veloped country settings. Despite being such a wide-ranging
disease affecting people from every demographic and socio-
economic group, adequate provision of health care services is
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lacking in most countries.14 Research to provide the evidence
basis for better provision of such services is hampered by
several issues, including heterogeneity in disease manifesta-
tion and difficulty in conducting large-scale, randomized in-
terventions.17 This is exacerbated by inconsistencies in
diagnostic criteria and staging of disease progression. Incon-
sistencies in staging criteria have been previously de-
scribed,18,19 with authors reporting difficulty in identifying
lymphedema stages20,21 or the lack of suitable data for meta-
analysis of study results.22
Current criteria to determine lymphedema stage display
a historically vertical approach to differential diagnosis and
management of lymphedema by disease causation. How-
ever, increasing global awareness of disability generally,
an increasing focus on rehabilitation and inclusion, and the
need to offer management strategies within populations
affected by multiple chronic diseases has created the need
to approach lymphedema from a more holistic view point.
This examination of current staging systems aims at
bringing together criteria commonly used in oncology, LF,
and podoconiosis settings to highlight similarities and
differences in staging descriptors. Combining the defining
features of lymphedema into a staging matrix rather than a
linear disease-specific scale may enable clinicians and
health workers in co-endemic areas, or with clients who
present with multiple forms of lymphedema, to more ac-
curately and consistently assess lymphedema progression.
Materials and Methods
Current and historical staging systems used to assess
lymphedema occurring from cancer therapies, LF, and po-
doconiosis were reviewed, as well as any assessment tech-
niques, diagnostic procedures, or clinical observations used.
Descriptors that determine each stage were entered into a
table, and the Common Terminology Criteria for Adverse
Events v5.0 (CTCAE)23 was used as a template to align the
severity of each stage across systems.
Designed for adverse events arising from cancer therapy,
the CTCAE offers unique clinical descriptions to determine
the severity for each adverse event based on a general
guideline, which includes symptoms, clinical presentation,
level of intervention required, and activities of daily living
(ADLs). ADLs are defined as either instrumental ADL—the
ability to prepare meals, shop for groceries or clothes, use
the telephone, manage money, etc., or self-care ADL—the
ability to manage bathing, dressing and undressing, feeding
self, using the toilet, and taking medications, without being
bedridden. There are five CTCAE grades; however, only
the first three grades are relevant to lymphedema. The five
CTCAE grades are:
 Grade 1: Mild, asymptomatic, or mild symptoms;
clinical or diagnostic observations only; intervention
not indicated.
 Grade 2: Moderate, minimal, local, or noninvasive in-
tervention indicated; limiting age-appropriate instru-
mental ADL.
 Grade 3: Severe or medically significant but not im-
mediately life-threatening; hospitalization or prolon-
gation of hospitalization indicated; disabling; limiting
self-care (ADL).
 Grade 4: Life-threatening consequences; urgent inter-
vention indicated.
 Grade 5: Death related to the adverse event.
A staging matrix was created by using separate domains for
edema (E), skin pathologies (S), and degree of disability (D),
and levels within each domain (range 0–3) were aligned to
common descriptors across systems. This three-domain, three-
level matrix produces a staging system in the format Ex.Sx.Dx.
Results
Several staging criteria are currently in use. The Interna-
tional Society of Lymphology (ISL) publishes a biannual
consensus document that initially described a three-stage
system.24 Later versions include reference to a latent, or
covert, stage of lymphedema,6 which is mostly relevant to
oncology-related lymphedema. More recently, the Interna-
tional Lymphedema Framework (ILF)25 has described a five-
stage system based on the ISL stages which includes a
definition for latent (stage 0) lymphedema, and it also splits
stage 2 into early and late substages (stages 2A and 2B). In
LF-related lymphedema, the World Health Organization
(WHO) initially recommended the use of a four-stage sys-
tem,26 later simplified to three stages7 but after publication of
a manual on management of LF-related lymphedema by
Dreyer et al.,27 a seven-stage system has been adopted. Al-
though the seven-stage system has been shown to have good
inter-rater reliability,28 researchers have collapsed these
stages into a simpler three-stage format of mild (stages 1 and
2), moderate (stage 3, or stages 3 and 4), and severe (stages 5
and 6, or stages 4–7).29,30 A five-stage system, adapted from
the Dreyer seven stages, has been developed and field tested
for lymphedema caused by podoconiosis.31 Although podo-
coniosis and LF-related lymphedema are frequently co-
endemic, the development of a podoconiosis-specific system
was driven by recognition of differences in the clinical pre-
sentation between the two etiologies. To overcome incon-
sistencies between staging systems, some researchers have
defined their own criteria for staging of disease-specific
lymphedema.32
Assessment techniques and lymphedema
staging systems
Various methods can be used to quantify the physiological
changes occurring in lymphedema, and in breast cancer-
related lymphedema, self-reported symptoms are also fre-
quently acknowledged.33,34 No single assessment procedure
or diagnostic test is accepted across all forms of lymphedema
and each staging system may use several different criteria to
determine each stage. The most commonly used assessment
tools are described first and then the staging systems are
described.
Assessment techniques, diagnostic criteria, and clinical
observations.
Reversal on limb elevation. The affected limb is observed
over time, usually overnight or after a period of prolonged
elevation, and any variation in observable swelling is noted.
The change in swelling may be the effect of resorption of
fluid into the venous system under low pressure conditions
and is an indication of the volume of free fluid accumulating
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in the subcutis. Swelling that does not reverse overnight in-
dicates that connective tissue overgrowth has begun, and that
accumulated fluid is less ‘‘free.’’
Comparison in circumference of the collateral limb. A
tape measure is used to record circumference measures of both
limbs at defined locations, frequently the ankle or wrist. This
measure is best used when there is an unaffected contralateral
limb. If the measure is taken over a muscle, an accounting for
limb dominance should be included in interpretation of the re-
sults. Circumference measures are useful to determine the size
of unilateral limb enlargement but do contribute to assessment
of underlying connective tissue change or skin pathologies.
Pitting test. A firm pressure is applied perpendicular to the
skin into the subcutaneous tissue by using a finger or thumb
and held until the underlying tissue deforms. The depth and
appearance of the pit will change with lymphedema pro-
gression. A deep pit with a rounded base that forms easily and
resolves slowly indicates that a protein-rich fluid is present
without significant fibrotic induration. Prolonged pressure
that produces a shallow pit with a flat base indicates that the
fluid load has been largely replaced by the growth of fibrotic
tissue or fatty deposits.
Stemmer sign. The skin is pinched and lifted away from the
underlying tissue, usually at the base of the toes or fingers.
Skin that cannot be lifted away from the subcutaneous tissue
(positive Stemmer sign) indicates an edema of lymphatic
origin, progressed enough to create subcutaneous connective
tissue changes. This test is frequently used in differential
diagnosis between edema of a lymphatic origin that will
produce a positive Stemmer sign and edema of a vascular
origin (phlebedema) that will produce a negative Stemmer
sign (skin can be lifted away from the underlying tissue).
Bio-impedance spectroscopy. A low-level, multi-
frequency electrical current is passed through the skin and
subcutaneous tissue via electrodes attached to the skin. Dif-
ferent frequencies detect resistance in fluid contained within
the cells (Ri) and free fluid in the extracellular compartment
(Re). The difference between these fluid compartments can
then be compared (Ri:Re). This test can be used to detect a
visually imperceptible edema as well as to quantify the free
fluid load in more pronounced edema. The stage of lym-
phedema should be considered in the interpretation of results
as although early-stage lymphedema is fluid rich, late-stage
lymphedema with heavy fibrosis and fat induration may have
little or no excess extracellular fluid.
Assessment of changes in the skin. As lymphedema pro-
gresses the epidermis becomes thickened (hyperkeratosis).
This may be accompanied by projections of fibrous and fatty
overgrowth in the underlying connective tissue appearing as
raised lesions—commonly called knobs, lumps, or bumps.
Papillomata, frequently referred to as mossy lesions, and
warty growths (verrucosis) may also form as the barrier
function of the skin is reduced. These skin changes are usu-
ally assessed visually but hyperkeratosis can also be assessed
by using skin callipers.
Staging systems.
Lymphedema stages as described by the ISL and ILF.
These are the only systems that include recognition of a stage
0 (latent lymphedema).6,25 Bio-impedance spectroscopy is
frequently used to monitor people at risk of arm lymphedema
after treatment for breast cancer to identify stage 0, and self-
reported symptoms may also be a valid assessment of this
stage.34,35 The criteria for each stage are determined by his-
tory, diagnostic investigation, clinical presentation, pitting
test, Stemmer sign, and skin changes. Reduction of edema on
elevation and the pitting test are used to differentiate stages 1
and 2, and stage 3 is defined by the presence of any skin
changes; however, there are no further distinctions as to the
degree of skin changes. This system is most commonly used
in developed country settings.
Lymphedema stages as described by the WHO. Devel-
oped specifically to assess LF-related lymphedema, this
system depends solely on clinical examination of affected
body parts.7,26 Stages 1 and 2 are differentiated by the re-
sponse to elevation, and stage 3 is defined by skin changes. If
stage 4 is used, this is defined by warty or nodular growths.
Other diagnostic criteria that may assist clinical decision
making such as the pitting test and Stemmer sign are not used.
Lymphedema stages described by Dreyer et al. Developed
specifically to assess progression in LF-related lymphedema,
this system also depends solely on clinical observation of
affected body parts.27 The stages progressively describe
changes observed as edema, which is reversible on elevation
(stage 1) and becomes irreversible (stage 2). Stage 3 recog-
nizes the combination of thickened skin and the presence of
underlying fibrotic induration that creates shallow folds in the
skin. In stage 4, knobs or bumps are present; stage 5 involves
deep skin folds that must be separated by hand to see the base;
and mossy lesions define stage 6. This system is the only one
to include any assessment of the level of disability experi-
enced, and stage 7 is defined by an inability to perform daily
self-care activities such as bathing and dressing without help.
Although this system appears to give a more detailed account
of lymphedema progression, neither the pitting test nor
Stemmer sign is used to determine the level of free fluid
remaining in the extracellular spaces.
Lymphedema stages described for podoconiosis. Devel-
oped specifically to determine progression in podoconiosis-
related lymphedema.31 This is caused by long-term barefoot
exposure to volcanic soils and can cause skin changes in the
feet earlier than in other forms of lymphedema. Stages 1 and 2
are still defined by the resolution of edema on elevation (or not),
but stage 2 is further defined as swelling that is present only
below the knee and may include knobs or bumps that, if
present, occur only below the ankle ormossy lesions around the
rim of the foot. Knobs and bumps above the ankle indicate
stage 3. Stage 4 describes swelling above the knee, and stage 5
is defined by joint fixation at the ankle or toes. This system also
allows for further descriptors by the addition of a circumference
measure and recording of the presence (M+) or absence (M-)
ofmossy changes. For example, an individual with stage 2,M-,
25 will have swelling below the knee without mossy lesions
and an ankle circumference of 25 cm.31
Alignment of the staging systems
The CTCAE23 is organized by anatomical or physiological
system, etiology, or purpose, and adverse events are listed
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within each system along with a description of severity
(grade). Categories relevant to lymphedema are general
disorders and administration site conditions (edema of the
limbs), musculoskeletal and connective tissue disorders (fi-
brosis of the connective tissues), and generalized edema de-
fined as ‘‘fluid accumulation in the tissues of the body
including the skin.’’ Not all CTCAE grades are appropriate
for staging and management of lymphedema, therefore
grades 4 (life-threatening) and 5 (death) were not used to
align the staging systems. Tables 1–3 give the CTCAE grades
relevant to edema and fibrosis. Table 4 aligns the lymphe-
dema staging systems with CTCAE grades 1–3.
Proposed lymphedema staging matrix
Based on the common descriptors that aligned across all
systems, three domains were created. Domains for swelling
and skin changes were ranked in terms of mild, moderate, and
severe. A scoring system for the disability domain could be
developed from a validated quality-of-life tool, linear scale,
or self-reported symptoms.36,37 Table 5 shows the proposed
staging matrix with descriptors and potential clinical tests.
Discussion
All staging systems differentiated stages 1 and 2 by ob-
servation of the edema after a period of elevation. Skin
changes were also used to define further stages, the podo-
coniosis system being the only one that included any skin
change at stage 2. Definitions of swelling were mostly limited
to whether there was any reversal on elevation or not, and
assessments of skin changes relied solely on visual assess-
ment. No system considered self-reported symptoms; how-
ever, studies on prevention of lymphedema after breast
cancer suggest that this may be a valid way to detect sub-
clinical edema.34
Each system presented a linear progression that was dis-
ease specific and could, therefore, result in a person with
significant skin changes but minimal swelling to be staged
‘‘higher’’ than someone with a grossly enlarged limb and
good skin integrity. This is problematic within the Dreyer
system, which has a fixed stage (stage 4) for the presence of
knobs (bumps lumps and skin protrusions), but these features
may begin to appear in some patients at an early stage or
remain absent in another patient with more advanced lym-
phedema. The linear nature of each system also makes it
difficult to correlate stages defined by skin changes with the
podoconiosis system. The appearance of mossy lesions in the
Dreyer system defines stage 6 but can be present at the feet in
podoconiosis at a much earlier stage (stage 2). The ISL/ILF
systems do not differentiate between the various skin fea-
tures, but they are the only systems that recognize that lym-
phedema has a latent or covert stage. Further, no system
adequately takes into account the level of disability that
lymphedema causes. The Dreyer system defines stage 7 as the
inability to perform self-care ADL but subtler degrees of
disability are not acknowledged. Podoconiosis stage 5 is
characterized by joint fixation but no degree of accompany-
ing disability is assessed. No staging systems account for the
frequency, duration, or severity of acute infections, even
though for many people with lymphedema these may be the
biggest contributors to disability, reduction in quality of life,
and dependence on others.
Only the podoconiosis criteria included objective mea-
sures of circumference and recording of specific skin changes
to further define the individual presentation for each case. The
use of such quantifiers in other staging systems could increase
their usefulness to clinicians and researchers in tracking the
benefits of interventions or progression over time.
Table 1. Common Terminology Criteria
for Adverse Events v5.0 Criteria for Limb Edema
Defined as ‘‘A Disorder Characterized
by Swelling Due to Excessive Fluid Accumulation
in the Upper or Lower Extremities’’
Grade Descriptor
1 5%–10% inter-limb discrepancy in volume or
circumference at point of greatest visible
difference, or swelling or obscuration of
anatomic architecture on close inspection
2 >10%–30% inter-limb discrepancy in volume
or circumference at point of greatest visible
difference, or readily apparent obscuration
of anatomic architecture, or obliteration of
skin folds, or readily apparent deviation
from normal anatomic contour, or limiting
instrumental ADL
3 >30% inter-limb discrepancy in volume, or
gross deviation from normal anatomic
contour, or limiting self-care ADL
ADL, activity of daily living.
Table 2 Common Terminology Criteria
for Adverse Events v5.0 Criteria for Fibrosis
Defined as ‘‘A Disorder Characterized by Fibrotic
Degeneration of the Connective Tissues’’
Grade Descriptor
1 Mild induration, able to move skin parallel to
plane (sliding) and perpendicular to skin
(pinching up)
2 Moderate induration, able to slide skin, unable
to pinch skin, or limiting instrumental ADL
3 Severe induration, unable to slide or pinch
skin, or limiting joint or orifice movement
(e.g., mouth, anus), or limiting self-care
ADL
Table 3. Common Terminology Criteria
for Adverse Events v5.0 Criteria for Generalized
Edema Defined as ‘‘Fluid Accumulation
in the Tissues of the Body Including the Skin’’
Grade Descriptor
1 Noted on exam; 1+ pitting edema
2 Interfering with instrumental ADLs; oral
therapy initiated
3 Interfering with self-care ADL; intravenous
therapy indicated; skin breakdown
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Few staging systems have undergone the rigorous reli-
ability analysis that was performed during development of
the podoconiosis system.31 One study reported a high level of
consistency in assessors using the Dreyer 7 stages but these
were experienced health workers who had 3 days of train-
ing,28 which is not representative of many real-life scenarios,
particularly in low-income settings. The podoconiosis system
was assessed after only a 2-hour training session for health
workers and reflects more accurately the level of training
likely to happen in podoconiosis and LF settings. We found
no reliability studies on staging systems in use in cancer-
related lymphedema.
Despite the availability of specific staging systems, re-
searchers and clinicians frequently find it convenient to
identify lymphedema status as mild, moderate, or severe.
When this is based on limb size, rather than the nature of any
skin or underlying tissue changes, it may be problematic in
all settings. A person with a very large limb who does not
Table 4. Lymphedema Staging Systems Aligned to Common Terminology Criteria for Adverse
Events v5.0 Grading Criteria
Stage ISL/ILF WHO Dreyer Podoconiosis
0 A subclinical state where
swelling is not evident.
May be present for
months/years before
clinical symptoms.
1 A visible swelling that
subsides with limb
elevation. Pitting test
may be negative. If
positive, will result in
deep pits only.
Mostly pitting edema and
spontaneously
reversible on elevation.
Lymphedema reversible
overnight.
Swelling reversible
overnight. The swelling
is not present when the
patient first gets up in
the morning.
2 Stage IIa
Limb elevation alone
rarely reduces swelling.
Deep pitting is manifest.
Mostly nonpitting edema
and not spontaneously
reversible on elevation.
Skin not thickened.
Irreversible lymphedema
with normal skin.
Below-knee swelling that is
not completely
reversible overnight; if
present, knobs/bumps
are only below the
ankle. Mossy changes
may be apparent in a
‘‘slipper’’ pattern
around the rim of the
foot.
Stage IIb
No, or only shallow
pitting. Tissue fibrosis is
more evident. There may
be fatty induration.
3 The tissue is hard (fibrotic)
and pitting is absent.
Skin changes such
as thickening,
hyperpigmentation,
increased skin folds, fat
deposits, and warty
overgrowths develop.
Edema not spontaneously
reversible on elevation.
Skin thickened, marked
dermatosclerosis with or
without papillomata.
Irreversible lymphedema
with thickened skin and
permanent shallow
folds, the base of which
is visible with joint
movement.
Below-knee swelling that is
not completely reversible
overnight; knobs/bumps
present above the ankle.
4 Edema not spontaneously
reversible on elevation.
Skin thickened with
warty/nodular or
papillomatous growth.
Irreversible lymphedema
with knobs (bumps and
lumps).
Above-knee swelling that is
not completely reversible
overnight; knobs/bumps
present at any location.
5 Irreversible lymphedema
with deep folds, the base
of which is visible when
separated by hand.
Joint fixation; swelling at
any place in the foot or
leg. The ankle or toe
joints become fixed and
difficult to flex or
dorsiflex. This may be
accompanied by apparent
shortening of the toes.
6 Irreversible lymphedema
with mossy lesions.
7 Irreversible lymphedema,
inability to do routine
activities adequately.
Bold fields align to CTCAE Grade 1, Italic fields align to CTCAE Grade 2, Bold and Italic fields align to CTCAE Grade 3.
CTCAE, Common Terminology Criteria for Adverse Events v5.0; ILF, International Lymphedema Framework; ISL, International
Society of Lymphology; WHO, World Health Organization.
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suffer debilitating infections or significant disability may be
considered severe, whereas another individual with a rela-
tively small limb but frequently debilitating secondary in-
fections may be rated as mild or moderate. In research
settings, whenever stages are grouped into broader clusters,
or are based on limb size alone, some sensitivity will be lost
in analysis of the outcomes of the intervention. In resource-
poor areas, it may also be useful for health care workers to
identify analogous disease stages to guide treatment; how-
ever, the currently available staging systems are inadequate
for this purpose.
Using the proposed matrix, a breast cancer patient pre-
senting with a large arm, significant fat induration but few
skin changes may be rated as E2:S0:D1, which tells the
reader that there is irreversible edema (underlying tissue
change) but the skin is in good order and the person is able to
perform most ADLs. A patient in rural Bangladesh with
lymphedema of filarial origin with significant swelling
around the ankle, deep skin folds, and a few knobs and
bumps may be rated as E2:S2:D1, which tells us that the
person has irreversible swelling, significant skin changes
without wounds, and is able to perform most instrumental
ADLs. A person in rural Ethiopia who has an early-stage
podoconiosis with ‘‘mossy’’ changes and multiple inter-
digital lesions but minimal swelling may be rated as
E1:S3:D0, which tells us that we should focus first on re-
storing skin integrity. Whether this matrix method of stag-
ing will permit some meta-analysis of previous studies
needs investigation. Any acceptable use of such a staging
format will require comprehensive development, including
clinical, research, and academic testing.
Recommendations
Lymphedema staging systems should capture the true
clinical presentation of lymphedema, aid in decision making
on appropriate treatment approaches, accurately reflect
lymphedema progression or improvement both within indi-
vidual cases and among cohorts, and provide meaningful
objective data for research purposes. Explanation of the cri-
teria used by differing staging systems offers here a resource
for clinicians, health workers, and researchers working in
settings where more than one form of lymphedema is present.
The aligning of the various staging systems suggests that fur-
ther work could be done to develop a matrix to enable much
needed meta-analysis on the evidence for lymphedema inter-
ventions. Such a matrix could also be used by health workers
on the ground where diseases of causation may be difficult to
differentiate without laboratory testing such as African coun-
tries which are co-endemic for LF and podoconiosis.
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